Ardelyx Presents Positive Data at DDW 2023 on IBSRELA®

IBSRELA provides meaningful reduction of multiple abdominal symptoms Patient-reported outcomes are strongly correlated with IBS-C abdominal symptom score WALTHAM, Mass., May 09, 2023 -- Ardelyx,... | May 9, 2023

Related Keywords

United States , Illinois , Chicago , Canada , China , Waltham , Japan , Fosun Pharma , Briane Lacy , Twitter , Nasdaq , Linkedin , Facebook , Drug Administration , Ardelyx Inc , Disease Week Conference , Patient Reported Treatment Satisfaction , Abdominal Score , Irritable Bowel Syndrome , Serious Dehydration , Prescribing Information , Boxed Warning , Kyowa Kirin , Knight Therapeutics , Ardelyx , Nc Stock Exchange , News , Information , Press Release , Bsrela , Rovides , Meaningful , Reduction , F , Multiple , Prabdominal , Symptoms , Outcomes , Fire , Strongly , Correlated , Ith , Symptom , Core , Bay , 023 Ardx Us0396971071 ,